Replies to post #368144 on Innovation Pharmaceuticals Inc (IPIX)

[sunspotter]

So all information that is already in the public domain.

Somewhat of a let down, then.

[frenchbroad]

Thank you for finding and posting this.

[zandant]

Good find and quite informative. Thanks.

[TheDane]

It’s nice to see this. Too bad they cancelled the conference. It shows what sissies some of our top leaders have devolved into. Anyway, here is a relevant quote from the abstract…

“ Successful clinical trials have shown Brilacidin exhibiting potent antibacterial activity in Phase 2 clinical trials for treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI), and anti-inflammatory activity demonstrated in Phase 2 clinical trials for treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis. Brilacidin received FDA Fast Track designation for the potential treatment of COVID-19 and currently is undergoing a Phase 2 clinical trial for treatment of moderate-to-severe COVID-19 in hospitalized patients.

[petemantx]

Great find. You are a true asset to the board in a major way.

As to the abstract itself, I found very little that had not already been known and PRd regarding Brilacidin. This abstract seemed like a summary rather than new information as to its properties.

I was expecting a great deal more from this abstract so overall I am a bit disappointed.

Disclaimer: I have erred many times as to my first response to many PRs and then later found out I was in error.

My question is do you feel this abstract is that bold and will make Brilacidin a major focal point in the Military Research community or will it be viewed more as a run of the mill abstract and not highlighted by many?

[farrell90]

Thanks the abstract will make a terrific PR next week.

Glta, Farrell

[olden_grumpini]

I found it interesting that the first reference to brilacidin included “(PMX-30063)”. I think this was a smart move to remind the conference of the past research that PolyMedix was doing with the DoD. You can find out more about that here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164656331

Other than that, it looks like a rehash of what’s already known and that I find to be disappointing. IPIX will likely issue a press release with the slide deck for the presentation and I hope there’s something new there.

BTW: I think the "PhD" designation for Weston and Harness are typos.

[Coondingy]

Thank you for finding this.

[Blue Fin]

Rocky, just saw your response to JFM, so here is the PM I sent you:
I have been sending Innovation Pharma PR'S and updates to John Carrol "Endpoints News" the last 2 yrs, (just sent the Abstract), never had a response but thought you might also send him the Abstract [e-mail]

For what its worth?

Others may also want to share it.

[DaubersUP]

Thanks. Good abstract summary

[wsbc]

Neither Kyle/Warren nor Jane are Phd's. Not sure why they're referenced as such.

[DaGreekster]

Can this Abstract from MHSRS be Stick Note posted? Please consider. Thanks.